Eksponeringen for vildagliptin efter en enkelt dosis hos patienter med let og moderat nedsat leverfunktion var reduceret (med henholdsvis 20% og 8%), mens eksponeringen for vildagliptin hos patienter med stærkt nedsat leverfunktion var øget med 22%.
The exposure to vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for patients with severe impairment was increased by 22%.